56161-89-8

Basic information

• Product Name: METHYL P-AMINOETHYLBENZOATE HCL
• Synonyms: METHYL P-AMINOETHYLBENZOATE HCL;Methyl p-aMinoethylbenzoate HCl/Methyl 4-(2-aMinoethyl)benzoate hydrochloride;Methyl 4-(2-amino-ethyl)-benzate hydrochloride;Benzoic acid, 4-(2-aminoethyl)-, methyl ester, hydrochloride (1:1);4-(2-Aminoethyl)benzoic acid methyl ester HCl
• CAS NO: 56161-89-8
• Molecular Formula: C₁₀H₁₃NO₂*ClH
• Molecular Weight: 215.68
• Mol File: 56161-89-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 292.8°C at 760 mmHg
• Flash Point: 149.7°C
• Appearance: /
• Vapor Pressure: 0.00179mmHg at 25°C
• CAS DataBase Reference: METHYL P-AMINOETHYLBENZOATE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL P-AMINOETHYLBENZOATE HCL(56161-89-8)
• EPA Substance Registry System: METHYL P-AMINOETHYLBENZOATE HCL(56161-89-8)

Safety Data

• Hazardous Substances Data: 56161-89-8(Hazardous Substances Data)

Usage

General Description

Methyl P-Aminoethylbenzoate HCL, also known as Benzocaine Hydrochloride, is a chemical compound that is primarily used as a local anesthetic. The substance works by inhibiting specificity of ion channels located on the nerve membrane that conduct pain signals to the brain, thus numbing a local area. It is often used in over-the-counter products like sore throat sprays, teething gels for infants, or in creams used for skin irritations. Despite its common usage, it can produce side effects like methemoglobinemia, a serious disorder that significantly reduces the amount of oxygen in the blood, particularly in infants or young children.

InChI:InChI=1/C10H13NO2.ClH/c1-13-10(12)9-4-2-8(3-5-9)6-7-11;/h2-5H,6-7,11H2,1H3;1H

Upstream product

• 1175530-38-7 4-((hydroxyiminomethyl)methyl)benzoic acid methyl ester 
• 67-56-1 methanol 
• 60531-36-4 4-(2-amino-ethyl)-benzoic acid hydrochloride 
• 1199-69-5 4-(2-aminoethyl)benzoic acid 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 

Downstream Products

• 857645-72-8 methyl 4-[2-({(2S)-5-{[(benzyloxy)carbonyl]amino}-2-[(tert-butoxycarbonyl)amino]pentanoyl}amino)ethyl]benzoate 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 958891-65-1 benzyl 4-(methoxycarbonyl)phenethylcarbamate 
• 1610605-42-9 methyl 4-(2-((tert-butoxycarbonyl)(ethyl)amino)ethyl)benzoate 
• 1175090-19-3 methyl 4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)benzoate 
• 90513-12-5 4‐(2‐aminoethyl)benzamide 

Relevant articles and documents

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation

Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activities were explored. Structure–activity relationship studies demonstrated the importance of the aminopentyl chain, the 3- or 4-fluorophenylaniline component, and the presence of at least one substituent, such as a tyramine moiety, attached directly to the triazine ring as essential for good activity. These compounds, represented by leads 4-{2-[4-(5-Aminopentylamino)-6-(3-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (6) and 4-{2-[4-(5-Aminopentylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (10), displayed moderate and significant in vitro and in vivo dual activities, respectively, and address the molecular link between inflammation and cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers a novel approach to the treatment of inflammation and cancer.

Occupying a flat subpocket in a tRNA-modifying enzyme with ordered or disordered side chains: Favorable or unfavorable for binding?

Small-molecule ligands binding with partial disorder or enhanced residual mobility are usually assumed as unfavorable with respect to their binding properties. Considering thermodynamics, disorder or residual mobility is entropically favorable and contrib